Drug Trial Radar · NCT02786901
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Last checked: Nov 19, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Jun 2016
Primary completion
Jun 13, 2017
Study completion Jul 1, 2017
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Loteprednol Etabonate Ophthalmic Gel, (BID and TID) versus Vehicle Group for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Conditions
- Cataract
- Pain
- Ocular Inflammation
Interventions
Loteprednol Etabonate Ophthalmic Gel dosed TIDDrug
Gel
Loteprednol Etabonate Ophthalmic Gel dosed BIDDrug
Gel
Vehicle GelDrug
Gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Complete Resolution of Anterior Chamber (AC) Cells at Visit 5 (Postoperative Day 8)Time frame: 8 days
- Number of Participants With Complete Resolution of Ocular Pain in Study Eye at Visit 5 (Postoperative Day 8)Time frame: 8 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 01
Phoenix, Arizona
Valeant Site 03
Oceanside, California
Valeant Site 05
Miami, Florida
Valeant Site 04
Quincy, Massachusetts
Valeant Site 06
Kansas City, Missouri
Valeant Site 02
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.